Article Details
Retrieved on: 2018-05-08 20:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>But that business plan changed under the guidance of venture capitalist Brook Byers, of the legendary Silicon Valley venture firm <b>Kleiner, Perkins, Caufield &</b> <b>Byers</b>. Byers saw the possibilities of monoclonal antibodies as diagnostic tools. By crafting antibodies to react with specific disease agents, ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here